Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Viewpoints_Dr. Stanley T. Crooke
PharmaShots Interview: n-Lorem Foundation’s Dr. Stanley T. Crooke Shares Insights on its Collaboration with Ultragenyx to Provide Personalized Medicines to Ultra-Rare Patients
In an interview with PharmaShots, Dr. Stanley T. Crooke, Founder, and Chief Executive Officer and Chairman of the Board at n-Lorem Foundation share his views on the collaboration with Ultragenyx. Shots: n-Lorem Foundation is the first & only foundation of its kind with a mission to provide life-saving treatments to patients who have diseases caused by extremely rare…
June 15, 2021
Viewpoints_Dr. Maria Ines Mitrani
PharmaShots Interview: Organicell’s Dr. Maria Ines Mitrani Shares Insights on the Zofin for COVID-19
In an interview with PharmaShots, Mari Mitrani, Chief Science Officer of Organicell shares her views on the positive results from the first ten COVID-19 patients treated with Zofin in India. Shots: This initial trial is being conducted in conjunction with Organicell's Indian partner, CWI India, which has entered into a product testing and distribution agreement with Organicell…
June 15, 2021
Viewpoints_Dr. Malcolm Barratt-Johnson
PharmaShots Interview: Albert Labs’ Dr. Malcolm Barratt-Johnson Shares Insights on Psychedelic-Assisted Therapies
In an interview with PharmaShots, Dr. Malcolm Barratt-Johnson, Chief Medical Officer of Albert Labs shared his views on the psychedelic therapies, the company's business model, and your plans for scaling the psychedelics therapies. Shots: Albert Labs will be the first psychedelics company to use an accelerated pathway, known as RWE studies, to swiftly provide access to patients…
June 11, 2021
Viewpoints_Mike Crichton
PharmaShots Interview: GSK’s Mike Crichton Shares Insights on the Approval of Benlysta in Europe
In an interview with PharmaShots, Mike Crichton, Senior Vice President, Global Therapy Area Head, Specialty & Primary Care at GSK shares his views on the European Commission's approval of Benlysta (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN). Shots: The European Commission approved the expanded use of GSK's…
June 8, 2021
Viewpoints_Dr. Gill Diamond and Joshua McClure
PharmaShots Interview: Maxwell Biosciences’ Dr. Gill Diamond and Joshua McClure Share Insights Novel Peptoids with Potent Antiviral Activity Against HSV-1 and SARS-CoV-2
In an interview with PharmaShots, Dr. Gill Diamond, Scientific Advisory Board Member and Joshua McClure, CEO and Co-founder of Maxwell Biosciences share their views on the news findings of the company published in MDI that demonstrated that several peptoids exhibit potent in vitro antiviral activity against both HSV-1 and SARS-CoV-2. Shots: The studies showed that antiviral peptoids…
June 7, 2021
Viewpoints_Rich Colvin
PharmaShots Interview: bluebird bio’s Rich Colvin Shares Insights on the Skysona to Treat Early Cerebral Adrenoleukodystrophy
In an interview with PharmaShots, Rich Colvin, M.D., Ph.D., Interim Chief Medical Officer at bluebird bio shares his views on the Skysona and its working on CALD patients. Shots: If granted marketing authorization, Skysona would be the first approved one-time gene therapy for CALD which is a rare neurogenerative disease with typically childhood onset The CHMP opinion…
June 4, 2021
Viewpoints_Ken Keller
PharmaShots Interview: Daiichi Sankyo’s Ken Keller Shares Insights on NICE Recommendation for Enhertu in HER2 Positive Breast Cancer
In an interview with PharmaShots, Ken Keller, President and Chief Executive Officer at Daiichi Sankyo and Global Head of the Daiichi Sankyo Oncology Business shared his views on the NICE CDF recommendation for Enhertu in unresectable or metastatic HER2 positive breast cancer and the company's growth and pipeline. Shots: The recommendation from NICE is based on the…
June 2, 2021
Viewpoints_Neil Solomons
PharmaShots Interview: Aurinia’s Neil Solomons Shares Insights on the Lupkynis
In an interview with PharmaShots, Neil Solomons, Co-founder and Chief Medical Officer of Aurinia shared his views on the data of Lupkynis (voclosporin) presented at the National Kidney Foundation 2021 Spring Clinical Meetings. Shots: New data analysis from the AURORA and AURA clinical studies shows that Aurinia's therapy demonstrated efficacy across all LN biopsy classes. These data show that treatment…
June 1, 2021
Viewpoints_Neil Moat
PharmaShots Interview: Abbott’s Neil Moat Shares Insights on the Next Generation TriClip Transcatheter Tricuspid Valve Repair System
In an interview with PharmaShots, Neil Moat, M.D., Chief Medical Officer of Abbott's Structural Heart Business shares his views on the CE mark approval of first-of-its-kind TriClip device. Shots: The new iteration of the device, called TriClip G4, offers new clip sizes and an enhanced leaflet grasping feature for physicians to further customize treatment to the complex tricuspid valve…
May 31, 2021
Load more